This comprehensive review examines the clinical impact of resmetirom, the first medication approved by the FDA for treating Metabolic Dysfunction-Associated Steatohepatitis (MASH). MASH is a severe form of fatty liver disease that affects up to 30% of people with metabolic dysfunction, often leading to liver fibrosis or cirrhosis. The review synthesizes current clinical guidance and real-world data on resmetirom, a selective thyroid hormone receptor-beta agonist designed to mimic the effects of thyroid hormones specifically in the liver to reduce fat accumulation. Clinical evidence shows that resmetirom successfully achieves both the resolution of MASH and the improvement of liver scarring (fibrosis) in non-cirrhotic patients. The drug is generally safe and well-tolerated, with treatment response appearing independent of traditional weight-loss therapies. A notable limitation is that it is not recommended for patients who have already progressed to full cirrhosis or those with untreated thyroid disorders.
This cross-sectional study explored how specific body composition—rather than just overall weight—affects functional disability in people suffering from chronic low back pain. Researchers evaluated 99 overweight and obese adults at a hospital in South India. Instead of relying solely on Body Mass Index (BMI), they used bioelectrical impedance to measure each person's exact ratio of fat to lean muscle. Participants also completed the Oswestry Disability Index (ODI) to gauge how back pain impacted their daily lives. The results were striking: 68.7% of participants had severe functional disability. Crucially, the researchers found that higher body fat mass was strongly associated with worse disability (r = 0.74), while having higher lean muscle mass was highly protective against disability (r = -0.67). Together, fat and muscle metrics explained 69% of the variance in patients' pain disability scores. The main limitation is the cross-sectional design, which captures a single moment in time and cannot definitively prove causation.
Researchers conducted a massive multicohort study to map the relationship between adult obesity and the risk of developing severe infections. Analyzing global burden estimates, the research team investigated how excess body weight impacts vulnerability to nearly 1,000 different infectious diseases. By looking at diverse populations across multiple cohorts, the researchers were able to establish a clear, overarching pattern: obesity significantly elevates the risk of experiencing severe outcomes from a wide array of infections, moving far beyond the well-documented risks associated with respiratory viruses like COVID-19. The study highlights a critical, often overlooked public health vulnerability. A limitation of such large-scale observational research is that it can be difficult to completely isolate obesity from other compounding lifestyle or socioeconomic factors that also influence infection risk.
This Phase 3 randomized trial, known as ACHIEVE-3, investigated the efficacy and safety of a novel medication called orforglipron compared to oral semaglutide in adults with type 2 diabetes. Current oral GLP-1 medications require strict fasting protocols—patients must take them on an empty stomach and wait before eating or drinking—which can be burdensome. Orforglipron is a non-peptide drug designed to bypass these strict fasting requirements. The study measured how well this new daily pill managed blood sugar and weight compared to oral semaglutide. The trial was designed as a non-inferiority study, aiming to prove that orforglipron is at least as effective as existing treatments, but with a significantly easier daily routine. A limitation is that long-term cardiovascular outcomes for this specific drug are still being studied, and full numerical data is pending wider publication.
A 72-week head-to-head RCT of 1,200 adults with obesity compared tirzepatide and semaglutide for weight maintenance after initial weight loss. Tirzepatide participants maintained 22% total body weight loss versus 15% for semaglutide, with superior improvements in insulin sensitivity and cardiovascular risk markers.